Gene therapy keeps aging organs healthier in mice
What if a single injection could keep your organs healthier into old age? In mice, that principle now works in practice.
FGF21 is a hormone-like substance the body produces in response to calorie restriction or low protein intake. It plays a key role in how the body regulates energy during scarcity. Researchers gave aged and geriatric mice a one-time injection with an AAV gene therapy, a method that uses a harmless virus to deliver a new gene to body cells, targeting muscle tissue. The therapy caused muscles to continuously produce FGF21.
The study, published in Molecular Therapy, shows that treated mice benefited across multiple systems. Body weight normalised. Insulin sensitivity improved. Liver function recovered. Kidneys showed less age-related damage. Heart and muscle performance improved. Cognitive function advanced as well.
Broad effects through a single signalling molecule
Tissue analysis confirmed the therapy also worked at the cellular level. Mitochondria (the energy-producing structures inside cells) functioned better. Protein balance, meaning the cell’s capacity to clear and replace damaged proteins, improved. Inflammation and fibrosis in organs decreased. The researchers also observed activation of AMPK, a protein considered an internal energy sensor of the cell that can slow aging processes.
What stands out is the breadth of effects. Most longevity interventions target a single mechanism or organ. FGF21 gene therapy appears to reach multiple systems simultaneously through central metabolic signals. That makes it an interesting candidate for further development, viewed through a longevity lens. That said, mouse studies are a starting point, not an endpoint. Whether comparable effects occur in humans remains unknown.
From calorie restriction to injection
Calorie restriction extends lifespan in many animals but is barely sustainable for humans. FGF21 is one of the key molecules that explains why calorie restriction works. A gene therapy mimicking this effect without hunger is a compelling concept. However, the path from mouse to human is long, and the safety of sustained FGF21 elevation in people has not yet been studied.